0,1,2
us-gaap:accountspayablecurrent,3102000000,FI2017Q4
us-gaap:accountspayablecurrent,3024000000,FI2018Q2
us-gaap:accountsreceivablenetcurrent,6873000000,FI2017Q4
us-gaap:accountsreceivablenetcurrent,7287000000,FI2018Q2
us-gaap:accountsreceivablenetcurrent,7240000000,FI2018Q2_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:accountsreceivablenetcurrent,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:accountsreceivablenetcurrent,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:accruedincometaxescurrent,708000000,FI2017Q4
us-gaap:accruedincometaxescurrent,661000000,FI2018Q2
us-gaap:accruedincometaxescurrent,656000000,FI2018Q2_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:accumulateddepreciationdepletionandamortizationpropertyplantandequipment,16602000000,FI2017Q4
us-gaap:accumulateddepreciationdepletionandamortizationpropertyplantandequipment,16567000000,FI2018Q2
us-gaap:additionalpaidincapitalcommonstock,39902000000,FI2017Q4
us-gaap:additionalpaidincapitalcommonstock,39741000000,FI2018Q2
us-gaap:allocatedsharebasedcompensationexpensenetoftax,57000000,FD2017Q2QTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,109000000,FD2017Q2YTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,77000000,FD2018Q2QTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,142000000,FD2018Q2YTD
us-gaap:allowancefordoubtfulaccountsreceivablecurrent,210000000,FI2017Q4
us-gaap:allowancefordoubtfulaccountsreceivablecurrent,210000000,FI2018Q2
us-gaap:amortizationofintangibleassets,9000000,FD2018Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember
us-gaap:amortizationofintangibleassets,17000000,FD2018Q2QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember
us-gaap:amortizationofintangibleassets,106000000,FD2018Q2QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_srt_ProductOrServiceAxis_mrk_AdempasMember
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,5000000,FD2017Q2QTD
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,4000000,FD2017Q2YTD
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,13000000,FD2018Q2QTD
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,15000000,FD2018Q2YTD
us-gaap:assets,87872000000,FI2017Q4
us-gaap:assets,85040000000,FI2018Q2
us-gaap:assetscurrent,24766000000,FI2017Q4
us-gaap:assetscurrent,24064000000,FI2018Q2
us-gaap:assetsfairvaluedisclosure,343000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,14970000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,15313000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,439000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,12967000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,13406000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,11000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,9000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,3000000,FI2018Q2
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,2000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,79000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,7000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,40000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,6000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,9000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,17000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,168000000,FI2018Q2
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,16000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,122000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,9000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,1000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,20000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,14976000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1548000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,9837000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,739000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,634000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,2059000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,159000000,FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,12752000000,FI2018Q2
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1456000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,8902000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,658000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,66000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1640000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,30000000,FI2018Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsaleequitysecuritiesaccumulatedgrossunrealizedgainbeforetax,16000000,FI2017Q4
us-gaap:availableforsaleequitysecuritiesaccumulatedgrossunrealizedlossbeforetax,6000000,FI2017Q4
us-gaap:availableforsaleequitysecuritiesamortizedcostbasis,265000000,FI2017Q4
us-gaap:availableforsalesecurities,15183000000,FI2017Q4
us-gaap:availableforsalesecuritiesaccumulatedgrossunrealizedgainbeforetax,27000000,FI2017Q4
us-gaap:availableforsalesecuritiesaccumulatedgrossunrealizedlossbeforetax,85000000,FI2017Q4
us-gaap:availableforsalesecuritiesamortizedcost,15241000000,FI2017Q4
us-gaap:availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsfairvalue,9600000000,FI2018Q2
us-gaap:availableforsalesecuritiesdebtsecurities,14908000000,FI2017Q4
us-gaap:availableforsalesecuritiesdebtsecurities,68000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1476000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9678000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,732000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,547000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1767000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1476000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9678000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,732000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,547000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1835000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1542000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9806000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,733000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,626000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,2042000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,12587000000,FI2018Q2
us-gaap:availableforsalesecuritiesdebtsecurities,1394000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,8684000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,649000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1396000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1394000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,8684000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,649000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1396000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1441000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,8782000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,649000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,65000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1620000000,FI2018Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecuritiescurrent,2300000000,FI2018Q2
us-gaap:availableforsalesecuritiesequitysecurities,275000000,FI2017Q4
us-gaap:businessacquisitionpercentageofvotinginterestsacquired,0.935,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businessacquisitionpercentageofvotinginterestsacquired,0.045,FI2017Q4_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationacquisitionoflessthan100percentnoncontrollinginterestfairvalue,25000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsideratio,108000000,FD2017Q2YTD
us-gaap:businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsideratio,122000000,FD2018Q2YTD
us-gaap:businesscombinationcontingentconsiderationliability,891000000,FI2016Q4
us-gaap:businesscombinationcontingentconsiderationliability,1002000000,FI2017Q2
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,830000000,FI2018Q2
us-gaap:businesscombinationcontingentconsiderationliability,830000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,830000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliabilitycurrent,92000000,FI2018Q2
us-gaap:businesscombinationindemnificationassetsamountasofacquisitiondate,37000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcontingentliabil,37000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcurrentassetsoth,32000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcurrentassetsoth,34000000,FI2018Q2_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumeddeferredtaxliabi,102000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedintangibles,297000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:cashandcashequivalentsatcarryingvalue,6092000000,FI2017Q4
us-gaap:cashandcashequivalentsatcarryingvalue,5310000000,FI2018Q2
us-gaap:cashandcashequivalentsatcarryingvalue,5300000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,6515000000,FI2016Q4
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,7786000000,FI2017Q2
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,6096000000,FI2017Q4
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,5312000000,FI2018Q2
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincluding,1271000000,FD2017Q2YTD
us-gaap:cashequivalentsatcarryingvalue,4500000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member
us-gaap:changeinunrealizedgainlossonfairvaluehedginginstruments1,31000000,FD2017Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonfairvaluehedginginstruments1,27000000,FD2017Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,15000000,FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,77000000,FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:commonstockdividendspersharedeclared,0.47,FD2017Q2QTD
us-gaap:commonstockdividendspersharedeclared,0.94,FD2017Q2YTD
us-gaap:commonstockdividendspersharedeclared,0.48,FD2018Q2QTD
us-gaap:commonstockdividendspersharedeclared,0.96,FD2018Q2YTD
us-gaap:commonstockparorstatedvaluepershare,0.50,FI2017Q4
us-gaap:commonstockparorstatedvaluepershare,0.50,FI2018Q2
us-gaap:commonstocksharesauthorized,6500000000,FI2017Q4
us-gaap:commonstocksharesauthorized,6500000000,FI2018Q2
us-gaap:commonstocksharesissued,3577000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,828000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,850000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577103522,FI2017Q4
us-gaap:commonstocksharesissued,3577000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,880000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577103522,FI2018Q2
us-gaap:commonstocksharesissued,3577000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,907000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstockvalue,1788000000,FI2017Q4
us-gaap:commonstockvalue,1788000000,FI2018Q2
us-gaap:comprehensiveincomenetoftax,1932000000,FD2017Q2QTD
us-gaap:comprehensiveincomenetoftax,3628000000,FD2017Q2YTD
us-gaap:comprehensiveincomenetoftax,1645000000,FD2018Q2QTD
us-gaap:comprehensiveincomenetoftax,2505000000,FD2018Q2YTD
us-gaap:costofgoodsandservicessold,3116000000,FD2017Q2QTD
us-gaap:costofgoodsandservicessold,6165000000,FD2017Q2YTD
us-gaap:costofgoodsandservicessold,3417000000,FD2018Q2QTD
us-gaap:costofgoodsandservicessold,3412000000,FD2018Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:costofgoodsandservicessold,6601000000,FD2018Q2YTD
us-gaap:costofgoodsandservicessold,6585000000,FD2018Q2YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,8000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,54000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member
us-gaap:debtandcapitalleaseobligations,24400000000,FI2017Q4
us-gaap:debtandcapitalleaseobligations,23300000000,FI2018Q2
us-gaap:debtcurrent,3057000000,FI2017Q4
us-gaap:debtcurrent,3379000000,FI2018Q2
us-gaap:debtcurrent,14000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_mrk_AccountingStandardUpdate201712Member
us-gaap:debtcurrent,14000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:debtinstrumentfaceamount,1000000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:debtinstrumentfaceamount,1150000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:debtinstrumentfaceamount,1000000000.0,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:debtinstrumentfairvalue,25600000000,FI2017Q4
us-gaap:debtinstrumentfairvalue,23900000000,FI2018Q2
us-gaap:debtinstrumentinterestratestatedpercentage,0.0185,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.02350,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.0240,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.03875,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.0500,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.013,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:deferredincometaxliabilitiesnet,2219000000,FI2017Q4
us-gaap:deferredincometaxliabilitiesnet,2159000000,FI2018Q2
us-gaap:deferredincometaxesandotherassetscurrent,4299000000,FI2017Q4
us-gaap:deferredincometaxesandotherassetscurrent,4005000000,FI2018Q2
us-gaap:deferredincometaxesandotherassetsnoncurrent,6075000000,FI2017Q4
us-gaap:deferredincometaxesandotherassetsnoncurrent,7145000000,FI2018Q2
us-gaap:deferredtaxliabilitiesundistributedforeignearnings,2000000000,FI2017Q4_us-gaap_TaxPeriodAxis_mrk_A2017TaxCutsandJobsActTCJAMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,3000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,8000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,2000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2017Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,7000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2018Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,17000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,2000000,FD2018Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,218000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,97000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,20000000,FD2017Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,436000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,191000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,39000000,FD2017Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,211000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,108000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,21000000,FD2018Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,425000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,221000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,41000000,FD2018Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,113000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,42000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,20000000,FD2017Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,226000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,83000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,40000000,FD2017Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,107000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,45000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,18000000,FD2018Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,215000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,91000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,35000000,FD2018Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,7000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,29000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,18000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,59000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,36000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,16000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,66000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,34000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,2000000,FD2017Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,5000000,FD2017Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,2000000,FD2018Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,6000000,FD2018Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,77000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,63000000,FD2017Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,14000000,FD2017Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,154000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,124000000,FD2017Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,28000000,FD2017Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,85000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,58000000,FD2018Q2QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,14000000,FD2018Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,168000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,125000000,FD2018Q2YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,28000000,FD2018Q2YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:depreciationdepletionandamortization,332000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,2355000000,FD2017Q2YTD
us-gaap:depreciationdepletionandamortization,702000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,332000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,2363000000,FD2018Q2YTD
us-gaap:depreciationdepletionandamortization,682000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:derivativeassetfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangementpoli,33000000,FI2017Q4
us-gaap:derivativeassetfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangementpoli,202000000,FI2018Q2
us-gaap:derivativeassetnotoffsetpolicyelectiondeduction,94000000,FI2017Q4
us-gaap:derivativeassetnotoffsetpolicyelectiondeduction,152000000,FI2018Q2
us-gaap:derivativeassets,130000000,FI2017Q4
us-gaap:derivativeassets,38000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,51000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,39000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,48000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,48000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,80000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,80000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,130000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,130000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,91000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,39000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,444000000,FI2018Q2
us-gaap:derivativeassets,83000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,153000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,208000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,302000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,302000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,142000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,142000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,444000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,444000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,236000000,FI2018Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,208000000,FI2018Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativecollateralobligationtoreturncash,3000000,FI2017Q4
us-gaap:derivativecollateralobligationtoreturncash,90000000,FI2018Q2
us-gaap:derivativeinstrumentsgainlossreclassificationfromaccumulatedocitoincomeestimatednetamounttob,29000000,FD2018Q2YTD
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,3000000,FD2017Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,49000000,FD2017Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,195000000,FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,14000000,FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,167000000,FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,5000000,FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember
us-gaap:derivativeliabilities,217000000,FI2017Q4
us-gaap:derivativeliabilities,71000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,90000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,3000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,1000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,52000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,162000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,162000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,55000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,55000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,217000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,217000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,127000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,90000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,197000000,FI2018Q2
us-gaap:derivativeliabilities,8000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,56000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,2000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,1000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,130000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,62000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,62000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,3000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,3000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,132000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,132000000,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,197000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,197000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,141000000,FI2018Q2_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,56000000,FI2018Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilityfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangement,123000000,FI2017Q4
us-gaap:derivativeliabilityfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangement,45000000,FI2018Q2
us-gaap:derivativeliabilitynotoffsetpolicyelectiondeduction,94000000,FI2017Q4
us-gaap:derivativeliabilitynotoffsetpolicyelectiondeduction,152000000,FI2018Q2
us-gaap:dividendscommonstockcash,2583000000,FD2017Q2YTD
us-gaap:dividendscommonstockcash,2583000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendscommonstockcash,2592000000,FD2018Q2YTD
us-gaap:dividendscommonstockcash,2592000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendspayablecurrent,1320000000,FI2017Q4
us-gaap:dividendspayablecurrent,1309000000,FI2018Q2
us-gaap:earningspersharebasic,0.71,FD2017Q2QTD
us-gaap:earningspersharebasic,1.28,FD2017Q2YTD
us-gaap:earningspersharebasic,0.64,FD2018Q2QTD
us-gaap:earningspersharebasic,0.91,FD2018Q2YTD
us-gaap:earningspersharediluted,0.71,FD2017Q2QTD
us-gaap:earningspersharediluted,1.27,FD2017Q2YTD
us-gaap:earningspersharediluted,0.63,FD2018Q2QTD
us-gaap:earningspersharediluted,0.90,FD2018Q2YTD
us-gaap:effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents,359000000,FD2017Q2YTD
us-gaap:effectiveincometaxratecontinuingoperations,0.200,FD2017Q2QTD
us-gaap:effectiveincometaxratecontinuingoperations,0.210,FD2017Q2YTD
us-gaap:effectiveincometaxratecontinuingoperations,0.178,FD2018Q2QTD
us-gaap:effectiveincometaxratecontinuingoperations,0.284,FD2018Q2YTD
us-gaap:employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized,758000000,FI2018Q2
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,25000000,FD2017Q2QTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,47000000,FD2017Q2YTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,13000000,FD2018Q2QTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,28000000,FD2018Q2YTD
us-gaap:equitysecuritiesfvni,104000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,104000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,375000000,FI2018Q2
us-gaap:equitysecuritiesfvni,164000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,164000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvniunrealizedgain,7000000,FD2018Q2QTD
us-gaap:equitysecuritiesfvniunrealizedgain,50000000,FD2018Q2YTD
us-gaap:equitysecuritieswithoutreadilydeterminablefairvalueamount,675000000,FI2018Q2
us-gaap:equitysecuritieswithoutreadilydeterminablefairvaluedownwardpriceadjustmentannualamount,26000000,FD2018Q2YTD
us-gaap:equitysecuritieswithoutreadilydeterminablefairvalueupwardpriceadjustmentannualamount,129000000,FD2018Q2YTD
us-gaap:escrowdeposit,176000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitypurchases,3000000,FD2017Q2YTD
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitypurchases,8000000,FD2018Q2YTD
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitysettlements,235000000,FD2018Q2YTD
us-gaap:gainlossrelatedtolitigationsettlement,115000000,D2018Q1Jan
us-gaap:goodwill,156000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:goodwill,18284000000,FI2017Q4
us-gaap:goodwill,18274000000,FI2018Q2
us-gaap:hedgedliabilitydiscontinuedfairvaluehedgecumulativeincreasedecrease,11000000,FI2017Q4
us-gaap:hedgedliabilitydiscontinuedfairvaluehedgecumulativeincreasedecrease,7000000,FI2018Q2
us-gaap:hedgedliabilityfairvaluehedge,983000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,5146000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,554000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,4511000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedgecumulativeincreasedecrease,5000000,FI2018Q2_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:impairmentofintangibleassetsexcludinggoodwill,131000000,FD2017Q2YTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,2439000000,FD2017Q2QTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,43000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6096000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,395000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,5590000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,111000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,4442000000,FD2017Q2YTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,186000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,11707000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,812000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,10751000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,144000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,2086000000,FD2018Q2QTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6302000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,450000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,5826000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,26000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,2085000000,FD2018Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,3432000000,FD2018Q2YTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,12582000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,864000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,11630000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,88000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,3419000000,FD2018Q2YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incomelossfromequitymethodinvestments,5000000,FD2017Q2QTD
us-gaap:incomelossfromequitymethodinvestments,5000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incomelossfromequitymethodinvestments,64000000,FD2018Q2QTD
us-gaap:incomelossfromequitymethodinvestments,66000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incomelossfromequitymethodinvestments,12000000,FD2018Q2YTD
us-gaap:incomelossfromequitymethodinvestments,16000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incometaxexpensebenefit,488000000,FD2017Q2QTD
us-gaap:incometaxexpensebenefit,935000000,FD2017Q2YTD
us-gaap:incometaxexpensebenefit,370000000,FD2018Q2QTD
us-gaap:incometaxexpensebenefit,369000000,FD2018Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incometaxexpensebenefit,975000000,FD2018Q2YTD
us-gaap:incometaxexpensebenefit,972000000,FD2018Q2YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:increasedecreaseinoperatingcapital,2337000000,FD2017Q2YTD
us-gaap:increasedecreaseinoperatingcapital,1274000000,FD2018Q2YTD
us-gaap:intangibleassetsnetexcludinggoodwill,14183000000,FI2017Q4
us-gaap:intangibleassetsnetexcludinggoodwill,12898000000,FI2018Q2
us-gaap:interestexpense,193000000,FD2017Q2QTD
us-gaap:interestexpense,193000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,375000000,FD2017Q2YTD
us-gaap:interestexpense,375000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,194000000,FD2018Q2QTD
us-gaap:interestexpense,194000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,379000000,FD2018Q2YTD
us-gaap:interestexpense,379000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestpaid,343000000,FD2017Q2YTD
us-gaap:interestpaid,341000000,FD2018Q2YTD
us-gaap:inventoryfinishedgoods,1334000000,FI2017Q4
us-gaap:inventoryfinishedgoods,1519000000,FI2018Q2
us-gaap:inventorygross,6238000000,FI2017Q4
us-gaap:inventorygross,6528000000,FI2018Q2
us-gaap:inventorynet,5096000000,FI2017Q4
us-gaap:inventorynet,5178000000,FI2018Q2
us-gaap:inventorynet,18000000,FI2018Q2_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:inventorynet,5196000000,FI2018Q2_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:inventorynoncurrent,1187000000,FI2017Q4
us-gaap:inventorynoncurrent,80000000,FI2017Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember
us-gaap:inventorynoncurrent,1100000000,FI2017Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember
us-gaap:inventorynoncurrent,1361000000,FI2018Q2
us-gaap:inventorynoncurrent,25000000,FI2018Q2_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember
us-gaap:inventorynoncurrent,1300000000,FI2018Q2_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember
us-gaap:inventoryworkinprocessandrawmaterials,4703000000,FI2017Q4
us-gaap:inventoryworkinprocessandrawmaterials,4818000000,FI2018Q2
us-gaap:investmentincomeinterest,96000000,FD2017Q2QTD
us-gaap:investmentincomeinterest,96000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,194000000,FD2017Q2YTD
us-gaap:investmentincomeinterest,194000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,81000000,FD2018Q2QTD
us-gaap:investmentincomeinterest,81000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,165000000,FD2018Q2YTD
us-gaap:investmentincomeinterest,165000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:liabilitiesandstockholdersequity,87872000000,FI2017Q4
us-gaap:liabilitiesandstockholdersequity,85040000000,FI2018Q2
us-gaap:liabilitiescurrent,18614000000,FI2017Q4
us-gaap:liabilitiescurrent,18128000000,FI2018Q2
us-gaap:liabilitiesfairvaluedisclosure,217000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,935000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,1152000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,197000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,830000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,1027000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:litigationreserve,160000000,FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember
us-gaap:litigationreserve,155000000,FI2018Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember
us-gaap:litigationsettlementamountawardedfromotherparty,200000000,D2016Q1Mar2016_srt_LitigationCaseAxis_mrk_GileadPatentCaseMember
us-gaap:litigationsettlementamountawardedfromotherparty,2540000000,D2016Q4Dec_srt_LitigationCaseAxis_mrk_GileadPatentCaseMember
us-gaap:litigationsettlementamountawardedtootherparty,4300000,D2018Q2April9_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember
us-gaap:litigationsettlementamountawardedtootherparty,27300000,FD2014Q4YTD_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_OnjLitigationMember
us-gaap:longtermdebtnoncurrent,21353000000,FI2017Q4
us-gaap:longtermdebtnoncurrent,19959000000,FI2018Q2
us-gaap:losscontingencyclaimsdismissednumber,650,D2014Q1Mar_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencyclaimsdismissednumber,1100,D2015Q3Nov_srt_ProductOrServiceAxis_mrk_JanuviaMember
us-gaap:losscontingencyclaimsdismissednumber,755,FD2018Q2YTD_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencynumberofplaintiffs,15,FD2018Q2YTD_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_CasesallegingcancerMember
us-gaap:losscontingencypendingclaimsnumber,275,FI2018Q2_srt_LitigationCaseAxis_mrk_CaliforniaStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,300,FI2018Q2_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,2630,FI2018Q2_srt_LitigationCaseAxis_mrk_NewJerseyMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,4,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,7,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_JanuviaMember
us-gaap:losscontingencypendingclaimsnumber,4,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_stpr_IL
us-gaap:losscontingencypendingclaimsnumber,1,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_srt_StatementGeographicalAxis_stpr_CA
us-gaap:losscontingencypendingclaimsnumber,1,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_srt_StatementGeographicalAxis_stpr_MA
us-gaap:losscontingencypendingclaimsnumber,1,FI2018Q2_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_srt_StatementGeographicalAxis_stpr_OH
us-gaap:losscontingencypendingclaimsnumber,3975,FI2018Q2_srt_ProductOrServiceAxis_mrk_FosamaxMember
us-gaap:losscontingencypendingclaimsnumber,3965,FI2018Q2_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,10,FI2018Q2_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_OnjLitigationMember
us-gaap:losscontingencypendingclaimsnumber,1260,FI2018Q2_srt_ProductOrServiceAxis_mrk_JanuviaMember
us-gaap:losscontingencypendingclaimsnumber,50,FI2018Q2_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember
us-gaap:losscontingencypendingclaimsnumber,600,FI2018Q2_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember
us-gaap:marketablesecuritiescurrent,2406000000,FI2017Q4
us-gaap:marketablesecuritiescurrent,2284000000,FI2018Q2
us-gaap:marketablesecuritiesnoncurrent,12125000000,FI2017Q4
us-gaap:marketablesecuritiesnoncurrent,10033000000,FI2018Q2
us-gaap:minorityinterest,233000000,FI2017Q4
us-gaap:minorityinterest,237000000,FI2018Q2
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,10000000,FD2018Q2YTD
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,10000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netcashprovidedbyusedininvestingactivities,2066000000,FD2017Q2YTD
us-gaap:netcashprovidedbyusedininvestingactivities,476000000,FD2018Q2YTD
us-gaap:netcashprovidedbyusedinoperatingactivities,3603000000,FD2017Q2YTD
us-gaap:netcashprovidedbyusedinoperatingactivities,4537000000,FD2018Q2YTD
us-gaap:netincomeloss,1946000000,FD2017Q2QTD
us-gaap:netincomeloss,3496000000,FD2017Q2YTD
us-gaap:netincomeloss,3496000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:netincomeloss,1707000000,FD2018Q2QTD
us-gaap:netincomeloss,1707000000,FD2018Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:netincomeloss,2443000000,FD2018Q2YTD
us-gaap:netincomeloss,2433000000,FD2018Q2YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:netincomeloss,2443000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:netincomelossattributabletononcontrollinginterest,5000000,FD2017Q2QTD
us-gaap:netincomelossattributabletononcontrollinginterest,11000000,FD2017Q2YTD
us-gaap:netincomelossattributabletononcontrollinginterest,11000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netincomelossattributabletononcontrollinginterest,9000000,FD2018Q2QTD
us-gaap:netincomelossattributabletononcontrollinginterest,14000000,FD2018Q2YTD
us-gaap:netincomelossattributabletononcontrollinginterest,14000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:newaccountingpronouncementorchangeinaccountingprinciplecumulativeeffectofchangeonequityornet,48000000,I2018Q1Jan1
us-gaap:newaccountingpronouncementorchangeinaccountingprinciplecumulativeeffectofchangeonequityornet,322000000,I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:noncontrollinginterestincreasefrombusinesscombination,25000000,FD2017Q2YTD
us-gaap:noncontrollinginterestincreasefrombusinesscombination,25000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:numberofinterestratederivativesheld,22,FI2018Q2
us-gaap:numberofinterestratederivativesheld,5,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:numberofinterestratederivativesheld,5,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:numberofinterestratederivativesheld,4,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:numberofinterestratederivativesheld,5,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:numberofinterestratederivativesheld,3,FI2018Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:numberofinterestratederivativesheld,4,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:numberofoperatingsegments,4,FD2018Q2YTD
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,29000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,26000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,25000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,113000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,238000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,265000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,84000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,18000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,26000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,29000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,47000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,215000000,FD2017Q2YTD
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,31000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,109000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,356000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,209000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,2000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,66000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,481000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,66000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,128000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,1000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,79000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,207000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,652000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,66000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,128000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,1000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,79000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,207000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,275000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,211000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,64000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,370000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,47000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,98000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,65000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,160000000,FI2018Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,645000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,47000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,98000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,211000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,65000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,224000000,FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,35000000,FD2017Q2QTD
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,78000000,FD2017Q2YTD
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,3000000,FD2018Q2QTD
us-gaap:othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionatt,47000000,FD2017Q2QTD
us-gaap:othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionatt,356000000,FD2017Q2YTD
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,3000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,4000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,115000000,FD2018Q2QTD
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,56000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,60000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,135000000,FD2018Q2YTD
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,18000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,122000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossafterreclassificationandtaxparent,266000000,FD2018Q2QTD
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossafterreclassificationandtaxparent,196000000,FD2018Q2YTD
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossbeforereclassificationandtax,264000000,FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossbeforereclassificationandtax,84000000,FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossreclassificationaftertax,73000000,FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossreclassificationaftertax,166000000,FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelossnetoftax,132000000,FD2017Q2YTD
us-gaap:othercomprehensiveincomelossnetoftax,132000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember
us-gaap:othercomprehensiveincomelossnetoftax,62000000,FD2018Q2YTD
us-gaap:othercomprehensiveincomelossnetoftax,62000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,47000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,35000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,47000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,132000000,FD2017Q2YTD
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,73000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,78000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,356000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,30000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,266000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,3000000,FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,62000000,FD2018Q2YTD
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,66000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,196000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:otherinventorysupplies,201000000,FI2017Q4
us-gaap:otherinventorysupplies,191000000,FI2018Q2
us-gaap:otherliabilitiescurrent,10427000000,FI2017Q4
us-gaap:otherliabilitiescurrent,9755000000,FI2018Q2
us-gaap:otherliabilitiescurrent,9746000000,FI2018Q2_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:otherliabilitiesnoncurrent,11117000000,FI2017Q4
us-gaap:otherliabilitiesnoncurrent,100000000,FI2017Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,150000000,FI2018Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,12028000000,FI2018Q2
us-gaap:otherliabilitiesnoncurrent,200000000,FI2018Q2_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,375000000,FI2018Q2_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:othernonoperatingincomeexpense,73000000,FD2017Q2QTD
us-gaap:othernonoperatingincomeexpense,143000000,FD2017Q2YTD
us-gaap:othernonoperatingincomeexpense,48000000,FD2018Q2QTD
us-gaap:othernonoperatingincomeexpense,340000000,FD2018Q2YTD
us-gaap:paymentforcontingentconsiderationliabilityinvestingactivities,175000000,FD2018Q2YTD_us-gaap_BusinessAcquisitionAxis_mrk_AfferentPharmaceuticalsMember
us-gaap:paymentsforproceedsfromotherinvestingactivities,274000000,FD2018Q2YTD
us-gaap:paymentsforrepurchaseofcommonstock,2153000000,FD2017Q2YTD
us-gaap:paymentsforrepurchaseofcommonstock,2162000000,FD2018Q2YTD
us-gaap:paymentsforrestructuring,505000000,FD2018Q2YTD
us-gaap:paymentsforrestructuring,389000000,FD2018Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:paymentsforrestructuring,116000000,FD2018Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:paymentsofdividendscommonstock,2601000000,FD2017Q2YTD
us-gaap:paymentsofdividendscommonstock,2610000000,FD2018Q2YTD
us-gaap:paymentstoacquireadditionalinterestinsubsidiaries,18000000,FD2017Q4QTD_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:paymentstoacquirebusinessesgross,358000000,D2017Q1Mar_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:paymentstoacquirebusinessesgross,502000000,D2018Q2June_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:paymentstoacquirebusinessesgross,378000000,D2018Q2June_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:paymentstoacquirebusinessesnetofcashacquired,347000000,FD2017Q2YTD
us-gaap:paymentstoacquirebusinessesnetofcashacquired,372000000,FD2018Q2YTD
us-gaap:paymentstoacquireintangibleassets,750000000,D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:paymentstoacquireintangibleassets,325000000,D2019Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,200000000,D2020Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,125000000,D2021Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,650000000,D2021Q1Mar01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,250000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:paymentstoacquiremarketablesecurities,6280000000,FD2017Q2YTD
us-gaap:paymentstoacquiremarketablesecurities,5248000000,FD2018Q2YTD
us-gaap:paymentstoacquireproductiveassets,732000000,FD2017Q2YTD
us-gaap:paymentstoacquireproductiveassets,1033000000,FD2018Q2YTD
us-gaap:proceedsfromdivestitureofbusinesses,65000000,D2018Q2April_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mrk_C3iMember
us-gaap:proceedsfromrepaymentsofshorttermdebt,2069000000,FD2018Q2YTD
us-gaap:proceedsfromsalematurityandcollectionsofinvestments,9363000000,FD2017Q2YTD
us-gaap:proceedsfromsalematurityandcollectionsofinvestments,7403000000,FD2018Q2YTD
us-gaap:proceedsfromsaleofintangibleassets,50000000,FD2017Q2YTD
us-gaap:proceedsfromsaleofintangibleassets,71000000,FD2018Q2YTD
us-gaap:proceedsfromstockoptionsexercised,408000000,FD2017Q2YTD
us-gaap:proceedsfromstockoptionsexercised,299000000,FD2018Q2YTD
us-gaap:profitloss,1951000000,FD2017Q2QTD
us-gaap:profitloss,3507000000,FD2017Q2YTD
us-gaap:profitloss,1716000000,FD2018Q2QTD
us-gaap:profitloss,2457000000,FD2018Q2YTD
us-gaap:propertyplantandequipmentnet,12439000000,FI2017Q4
us-gaap:propertyplantandequipmentnet,12626000000,FI2018Q2
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,15000000,FD2017Q2QTD
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,50000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,139000000,FD2017Q2YTD
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,145000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,49000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,6000000,FD2017Q2QTD
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,33000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,83000000,FD2017Q2YTD
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,94000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,31000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodtax,9000000,FD2017Q2QTD
us-gaap:reclassificationfromaocicurrentperiodtax,17000000,FD2017Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodtax,56000000,FD2017Q2YTD
us-gaap:reclassificationfromaocicurrentperiodtax,51000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodtax,18000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:repaymentsoflongtermdebt,301000000,FD2017Q2YTD
us-gaap:repaymentsoflongtermdebt,3008000000,FD2018Q2YTD
us-gaap:researchanddevelopmentexpense,1782000000,FD2017Q2QTD
us-gaap:researchanddevelopmentexpense,1560000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,3612000000,FD2017Q2YTD
us-gaap:researchanddevelopmentexpense,3191000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,2350000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:researchanddevelopmentexpense,2274000000,FD2018Q2QTD
us-gaap:researchanddevelopmentexpense,2041000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,344000000,FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:researchanddevelopmentexpense,5470000000,FD2018Q2YTD
us-gaap:researchanddevelopmentexpense,5023000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,1400000000,FD2018Q2YTD_srt_CounterpartyNameAxis_mrk_EisaiMember
us-gaap:researchanddevelopmentexpense,344000000,FD2018Q2YTD_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:restrictedcashandcashequivalents,4000000,FI2017Q4
us-gaap:restrictedcashandcashequivalents,2000000,FI2018Q2
us-gaap:restructuringandrelatedcostcostincurredtodate1,13800000000,FI2018Q2
us-gaap:restructuringandrelatedcostexpectedcostremaining1,500000000,FI2018Q2
us-gaap:restructuringandrelatedcostincurredcost,210000000,FD2017Q2QTD
us-gaap:restructuringandrelatedcostincurredcost,33000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,37000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,9000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,8000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,166000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,118000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,48000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,6000000,FD2017Q2QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,118000000,FD2017Q2QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,86000000,FD2017Q2QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,425000000,FD2017Q2YTD
us-gaap:restructuringandrelatedcostincurredcost,96000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,47000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,49000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,9000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,6000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,317000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,202000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,115000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,55000000,FD2017Q2YTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,202000000,FD2017Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,168000000,FD2017Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,235000000,FD2018Q2QTD
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,228000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,200000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,28000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,200000000,FD2018Q2QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,35000000,FD2018Q2QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,339000000,FD2018Q2YTD
us-gaap:restructuringandrelatedcostincurredcost,9000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,9000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,5000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,8000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,323000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,255000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,68000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,255000000,FD2018Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,86000000,FD2018Q2YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,475,FD2017Q2QTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,1020,FD2017Q2YTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,635,FD2018Q2QTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,1345,FD2018Q2YTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminatedinceptiontodate,44695,FI2018Q2
us-gaap:restructuringcharges,166000000,FD2017Q2QTD
us-gaap:restructuringcharges,166000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,317000000,FD2017Q2YTD
us-gaap:restructuringcharges,317000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,228000000,FD2018Q2QTD
us-gaap:restructuringcharges,228000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,323000000,FD2018Q2YTD
us-gaap:restructuringcharges,323000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringreserve,747000000,FI2017Q4
us-gaap:restructuringreserve,619000000,FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringreserve,128000000,FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringreserve,590000000,FI2018Q2
us-gaap:restructuringreserve,485000000,FI2018Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringreserve,105000000,FI2018Q2_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:retainedearningsaccumulateddeficit,41350000000,FI2017Q4
us-gaap:retainedearningsaccumulateddeficit,41523000000,FI2018Q2
us-gaap:retainedearningsaccumulateddeficit,41508000000,FI2018Q2_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:retainedearningsaccumulateddeficit,266000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_mrk_AccountingStandardUpdate201802Member
us-gaap:retainedearningsaccumulateddeficit,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:retainedearningsaccumulateddeficit,8000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member
us-gaap:retainedearningsaccumulateddeficit,54000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member
us-gaap:retainedearningsaccumulateddeficit,322000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:revenues,9930000000,FD2017Q2QTD
us-gaap:revenues,115000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,8000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,108000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,9815000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,67000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,67000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,89000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,89000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,63000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,63000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,25000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,28000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,54000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,109000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,163000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,6000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,106000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,112000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,167000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,206000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,373000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,3000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,116000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,119000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,53000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,50000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,103000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,63000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,69000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,60000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,143000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,32000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,47000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,79000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,65000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,66000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,312000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,469000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,125000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,53000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,178000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,93000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,57000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,150000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,136000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,146000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,282000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,248000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,315000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,563000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,541000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,407000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,948000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,556000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,325000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,881000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,103000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,479000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,582000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,21000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,64000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,85000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,77000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,78000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,155000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,153000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,47000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,199000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,304000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,761000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1064000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,104000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,61000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,166000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,70000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,341000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,58000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,399000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,208000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,208000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,72000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,51000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,123000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,199000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,199000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,6000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,197000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,203000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,61000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,65000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,30000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,152000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,182000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,256000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,261000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,517000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,122000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,246000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,367000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,107000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,160000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4300000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,270000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,3929000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,101000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,5515000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,685000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,4830000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,955000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,8759000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,101000000,FD2017Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,839000000,FD2017Q2QTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,4308000000,FD2017Q2QTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,5623000000,FD2017Q2QTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,340000000,FD2017Q2QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,1056000000,FD2017Q2QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,583000000,FD2017Q2QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,2804000000,FD2017Q2QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,49000000,FD2017Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
us-gaap:revenues,19365000000,FD2017Q2YTD
us-gaap:revenues,332000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,66000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,266000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,19033000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,151000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,151000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,192000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,192000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,112000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,112000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,45000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,49000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,211000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,310000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,11000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,222000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,233000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,330000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,403000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,733000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,6000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,226000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,231000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,107000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,92000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,198000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,139000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,12000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,151000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,169000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,107000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,276000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,74000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,86000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,160000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,124000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,127000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,711000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,290000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1001000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,257000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,92000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,349000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,175000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,111000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,286000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,279000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,308000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,587000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,442000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,617000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1059000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1048000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,740000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1787000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,917000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,547000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1465000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,223000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,938000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1161000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,39000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,185000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,224000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,142000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,154000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,296000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,265000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,359000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,611000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1449000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2062000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,219000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,110000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,329000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,132000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,133000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,639000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,115000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,754000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,437000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,437000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,251000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,96000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,347000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,383000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,383000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,12000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,377000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,389000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,126000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,130000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,120000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,303000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,423000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,455000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,440000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,895000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,233000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,468000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,701000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,216000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,97000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,313000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,8437000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,553000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,7690000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,194000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,10596000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,1341000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,9255000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1894000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,16944000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,195000000,FD2017Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,1544000000,FD2017Q2YTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,8503000000,FD2017Q2YTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,10862000000,FD2017Q2YTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,763000000,FD2017Q2YTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,2054000000,FD2017Q2YTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,1068000000,FD2017Q2YTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,5433000000,FD2017Q2YTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,144000000,FD2017Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
us-gaap:revenues,500000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_srt_ProductOrServiceAxis_mrk_AdempasMember
us-gaap:revenues,10465000000,FD2018Q2QTD
us-gaap:revenues,37000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,54000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,10428000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,75000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,75000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,31000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,13000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,44000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,84000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,84000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,101000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,101000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,29000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,42000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,95000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,145000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,240000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,87000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,204000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,253000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,457000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,7000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,118000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,125000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,48000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,46000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,35000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,7000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,42000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,89000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,59000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,148000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,27000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,43000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,70000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,59000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,302000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,306000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,608000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,114000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,60000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,174000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,87000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,63000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,149000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,132000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,174000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,305000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,209000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,377000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,585000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,503000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,446000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,949000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,959000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,707000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1667000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,35000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,35000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,107000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,526000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,633000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,81000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,81000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,87000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,100000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,188000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,187000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,49000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,236000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,289000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,765000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1053000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,122000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,193000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,68000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,68000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,356000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,70000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,426000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,157000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,157000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,57000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,233000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,233000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,180000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,185000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,54000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,152000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,155000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,123000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,113000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,8000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,218000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,226000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,43000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,44000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4189000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,311000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,3822000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,6240000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,779000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,5461000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1090000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,9282000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,855000000,FD2018Q2QTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,4243000000,FD2018Q2QTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,6222000000,FD2018Q2QTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,279000000,FD2018Q2QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,1350000000,FD2018Q2QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,594000000,FD2018Q2QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,3144000000,FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,10459000000,FD2018Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:revenues,20502000000,FD2018Q2YTD
us-gaap:revenues,6000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,80000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,20496000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,143000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,143000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,55000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,22000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,76000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,166000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,166000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,174000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,174000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,73000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,125000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,175000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,269000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,444000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,7000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,171000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,178000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,387000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,482000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,869000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,14000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,231000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,245000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,95000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,97000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,192000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,85000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,14000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,168000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,105000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,273000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,81000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,138000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,113000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,114000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,682000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,586000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1269000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,242000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,106000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,348000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,177000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,123000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,300000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,260000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,326000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,586000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,401000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,729000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1129000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,968000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,862000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1829000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1797000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1333000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3131000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,35000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,35000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,231000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1055000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1286000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,2000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,201000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,203000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,168000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,195000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,363000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,357000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,95000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,452000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,563000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1483000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2045000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,234000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,372000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,135000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,140000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,668000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,150000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,818000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,324000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,324000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,250000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,349000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,464000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,464000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,11000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,350000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,360000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,111000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,113000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,11000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,311000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,322000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,253000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,243000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,25000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,505000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,531000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,17000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,91000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,108000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,8296000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,618000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,7538000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,140000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,12200000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,1537000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,10663000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2155000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,18201000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,140000000,FD2018Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,1592000000,FD2018Q2YTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,8376000000,FD2018Q2YTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,12126000000,FD2018Q2YTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,486000000,FD2018Q2YTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,2588000000,FD2018Q2YTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,1126000000,FD2018Q2YTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,6334000000,FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,20473000000,FD2018Q2YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:sellinggeneralandadministrativeexpense,2500000000,FD2017Q2QTD
us-gaap:sellinggeneralandadministrativeexpense,4972000000,FD2017Q2YTD
us-gaap:sellinggeneralandadministrativeexpense,2508000000,FD2018Q2QTD
us-gaap:sellinggeneralandadministrativeexpense,5016000000,FD2018Q2YTD
us-gaap:sharebasedcompensation,82000000,FD2017Q2QTD
us-gaap:sharebasedcompensation,156000000,FD2017Q2YTD
us-gaap:sharebasedcompensation,90000000,FD2018Q2QTD
us-gaap:sharebasedcompensation,170000000,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,1000000,FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,5000000,FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,855000,FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,7000000,FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,63.62,FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,63.97,FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,56.70,FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,58.15,FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpecteddividen,0.036,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpecteddividen,0.034,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatil,0.179,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatil,0.191,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinteres,0.020,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinteres,0.028,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod,4000000,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod,3000000,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverag,7.05,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverag,8.19,FD2018Q2YTD
us-gaap:sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedavera,63.98,FD2017Q2YTD
us-gaap:sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedavera,57.72,FD2018Q2YTD
us-gaap:stockholdersequity,34336000000,FI2017Q4
us-gaap:stockholdersequity,32529000000,FI2018Q2
us-gaap:stockholdersequitybeforetreasurystock,78130000000,FI2017Q4
us-gaap:stockholdersequitybeforetreasurystock,77930000000,FI2018Q2
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,40308000000,FI2016Q4
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,338000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39939000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,220000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,44133000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,106000000,FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,40000000,FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39712000000,FI2017Q2
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,75000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39776000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,249000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,45046000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,34569000000,FI2017Q4
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39902000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,233000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,41350000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,32766000000,FI2018Q2
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,65000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39741000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,237000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,41523000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityother,163000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityother,161000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityothershares,12000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:stockholdersequityothershares,10000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockshares,880491914,FI2017Q4
us-gaap:treasurystockshares,907061576,FI2018Q2
us-gaap:treasurystocksharesacquired,34000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystocksharesacquired,37000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalue,43794000000,FI2017Q4
us-gaap:treasurystockvalue,45401000000,FI2018Q2
us-gaap:treasurystockvalueacquiredcostmethod,2153000000,FD2017Q2YTD
us-gaap:treasurystockvalueacquiredcostmethod,2153000000,FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalueacquiredcostmethod,2162000000,FD2018Q2YTD
us-gaap:treasurystockvalueacquiredcostmethod,2162000000,FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,18000000,FD2017Q2QTD
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,20000000,FD2017Q2YTD
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,13000000,FD2018Q2QTD
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,13000000,FD2018Q2YTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2752000000,FD2017Q2QTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2759000000,FD2017Q2YTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2696000000,FD2018Q2QTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2702000000,FD2018Q2YTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2734000000,FD2017Q2QTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2739000000,FD2017Q2YTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2683000000,FD2018Q2QTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2689000000,FD2018Q2YTD
